1699-19-0

Basic information

• Product Name: 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidine-2,4(1H,3H)-dione
• CAS NO: 1699-19-0
• Molecular Formula: C₁₀H₁₄N₂O₂
• Molecular Weight: 194.2304
• Mol File: 1699-19-0.mol
• Article Data: 1

Chemical Properties

• Density: 1.21g/cm³
• Refractive Index: 1.556
• CAS DataBase Reference: 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidine-2,4(1H,3H)-dione(1699-19-0)
• EPA Substance Registry System: 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidine-2,4(1H,3H)-dione(1699-19-0)

Safety Data

• Hazardous Substances Data: 1699-19-0(Hazardous Substances Data)

Upstream product

• 5452-73-3 methyl 2-oxocyclooctanecarboxylate 
• 502-49-8 cycloactanone 

Relevant articles and documents

Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer

Valosine containing protein (VCP/p97) is a member of the AAA ATPase family involved in several essential cellular functions and plays an important role in the ubiquitin-mediated degradation of misfolded proteins. P97 has a significant role in maintaining the cellular protein homeostasis for tumor cell growth and survival and has been found overexpressed in many tumor types. No new molecule entities based on p97 target were approved in clinic. Herein, a series of novel pyrimidine structures as p97 inhibitors were designed and synthesized. After enzymatic evaluations, structure-activity relationships (SAR) were discussed in detailed. Among the screened compounds, derivative 35 showed excellent enzymatic inhibitory activity (IC50, 36 nM). The cellular inhibition results showed that compound 35 had good antiproliferative activity against the non-small cell lung cancer A549 cells (IC50, 1.61 μM). Liver microsome stability showed that the half-life of compound 35 in human liver microsome was 42.3 min, which was more stable than the control CB-5083 (25.8 min). The in vivo pharmacokinetic results showed that the elimination phase half-lives of compound 35 were 4.57 h for ig and 3.64 h for iv, respectively and the oral bioavailability was only 4.5%. These results indicated that compound 35 could be effective for intravenous treatment of non-small cell lung cancer.